Kornimate/medical-research-clean huggingface dataset:
study on the effect of transcranial magnetic stimulation in mild to moderate alzheimer's disease

Conditions: Mild to Moderate Alzheimer Disease

Summary: the investigators will compare cognitition, mood (depression), adl, and brain structural and functional mri before and after 4-week transcranial magnetic stimulation in patients with mild to moderate alzheimer's disease. the investigators also compare the change of cognitition, mood (depression), adl, and brain structural and functional mri between tms group and sham coil group.

each 16 patients will be allocated to tms group and sham coil group. before tms/sham coil stimulation, the investigators will take fmri of each patient, and figure out which focus has strongest connectivity to hippocampus among lateral parietal regions of the brain. the investigators will fix the tsm transduced and apply accurate tms stimulation to the focus using personalized frames. the investigators will make the frame using 3d printing technology. after 4 week- tms stimulation, the investigators will compare cognitition, mood (depression), adl, and brain structural and functional mri beween baseline and after intervention. the investigators also compare the change of cognitition, mood (depression), adl, and brain structural and functional mri between tms group and sham coil group.

Eligibility criteria:
inclusion criteria: * patients who visited memory clinic of samsung medical center * aged 55 \~ 90 * diagnosed as probable alzheimer dementia according to nia-aa guideline 2011, or mci patiens with amyloid pet positivity * below -1sd in svltdelayed recall test and rcft delayed recall test * k-mmse \>=18 * no epileptic discharge in eeg * no history of epilepsy * no arrhythmia or mi in ecg * can read and write korean (literate) * volunteer and agree to the registration exclusion criteria: * no other neurologic deficit which can cause dementia except for alzheimer's disease * paitient who has severe cerebral white matter hyperintensities. (deep white matter \>=2.5cm and caps or band \>=1.0 cm) * patients with severe medical disease including caner and ishemic heart disease * claustrophobia or allergic to contrast of mri * medical deviced which is not removable (e.g pacemaker, cochlear implantation, dental prosthesis) * history of brain surgery, and intervension or surgery of intra/extracranial artery(e.g. carotid artery stent insertion, cea) * patient with dyspnea during resting * history of loss of consciousness for more than 1 hour except for general anesthesia * patients who cannot read written material because of poor visual acuity * patients who cannot communicate because of severe hearing difficulty * history of ototoxicity medication or exposure severe noises * determined as inapropriate to participate clinical trial
clinical study comparing two models of a travoprost intraocular implant

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: phase iii study to compare the safety and efficacy of intraocular implants containing travoprost at two different elution rates versus timolol maleate ophthalmic solution, 0.5% (timolol) in reducing elevated intraocular pressure in subjects with open angle glaucoma (oag) or ocular hypertension (oht)

this is a prospective, randomized, double-masked, active-controlled, parallel-group, multi-center trial comparing the efficacy and safety of the model g2tr-063 travoprost intraocular implant and the model g2tr-125 travoprost intraocular implant to topical timolol in subjects with oag or oht. the staff who record key efficacy measures and the study subjects will remain masked to study treatment.

Eligibility criteria:
inclusion criteria: * diagnosed with open-angle glaucoma or ocular hypertension * c/d ratio ≤ 0.8 * zero to two preoperative ocular hypotensive medications exclusion criteria: * active corneal inflammation or edema * retinal disorders not associated with glaucoma
demonstration of broncholytic effects in subjects with obstructive airway diseases by low frequency ultrasound

Conditions: Healthy Volunteers; COPD GOLD I to IV; Asthma GINA 1 to 4

Summary: this study is aiming at evaluating whether low frequency ultrasound spectroscopy is a sensitive tool to detect broncholytic effects in patients with obstructive airway diseases.


Eligibility criteria:
inclusion criteria: * • 18 - 70 years * for the healthy cohort: * fev1 \> 80 % pred, fev1/fvc ≥ 70 % pred., no history of allergies or asthma * nonsmokers, with a history of less than 1 packyear having been nonsmokers for at least the last five years * for the copd cohort: copd gold i to iv according to current guidelines (2) * for the asthma cohort: history of asthma gina i to iv according to current guidelines (3) * bmi ≤ 30 kg/m2 * able and willing to give written informed consent * available to complete all study measurements exclusion criteria: * • medical conditions which prohibit the use of salbutamol * recent exacerbation of copd or asthma or lower respiratory tract infection (four weeks previous to informed consent visit) * past or present disease, which as judged by the investigator, may affect the outcome of the study. these diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, psychiatric disease, endocrine disease or pulmonary disease (including but not confined to asthma, tuberculosis, bronchiectasis or cystic fibrosis) * history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol assignment * risk of non-compliance with study procedures * suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.
evaluation of reflex tear production

Conditions: Dry Eye Disease

Summary: the purpose of this study is to evaluate reflex tear production following cotton swab nasal stimulation in subjects with dry eye disease (ded).

the primary analysis will assess the change from baseline (pre- versus immediately post-cotton swab nasal stimulation) in tear meniscus height (tmh) using optical coherence tomography (oct). this study will consist of one visit on a single day.

Eligibility criteria:
key inclusion criteria: * within the last 12 months, have a previous history of dry eye disease, either clinician diagnosed or patient reported. * within the last 6 months, have used, or desired to use artificial tears for dry eye symptoms. * corrected visual acuity (snellen) 20/200 or better in both eyes. * good general and ocular health, as determined by the investigator using medical history, ophthalmic examination and history. * able, as assessed by the investigator, and willing to follow study instructions. * other protocol-specified inclusion criteria may apply. key exclusion criteria: * current evidence of any clinically significant ophthalmic disease other than dry eye (for example, glaucoma or macular degeneration). * use of artificial tears within 2 hours of the study visit. * history of ocular surgery within 1 year of the study visit. * use of contact lenses in either eye within 7 days of the study visit. * use of lid hygiene (all forms of lid care) or heat masks within 7 days of the study visit. * use of any topical ocular anti-inflammatory medications, any topical ocular corticosteroid, or any non-steroidal-anti-inflammatory agents within 30 days of the study visit. * other protocol-specified exclusion criteria may apply.

Keywords: reflex tear production
trial of wireless capsule endoscopy in the evaluation of obscure gastrointestinal bleeding

Conditions: Obscure Gastrointestinal Bleeding (Occult or Overt)

Summary: this study compares wireless capsule endoscopy (patients swallow a pill-size camera that sends pictures of the intestine to a recorder worn on their belt) to an x-ray study (called dedicated small bowel contrast radiography) in patients who have bleeding from the gastrointestinal tract without a source of the bleeding identified on routine endoscopic examinations of the esophagus (food pipe), stomach, small intestine, and large intestine. the investigators hope to determine if the capsule is a better test in terms of decreasing further bleeding, decreasing the need for further diagnostic testing, and decreasing the need for blood transfusions and time spent in the hospital.


Eligibility criteria:
inclusion criteria: 1. iron deficiency anemia in men or post-menopausal women and positive fecal occult blood test in pre-menopausal women with nondiagnostic upper endoscopy, colonoscopy, and push enteroscopy. 2. persistent or recurrent melena or hematochezia with nondiagnostic upper endoscopy, colonoscopy, and push enteroscopy. exclusion criteria: 1. known or suspected gi tract obstruction 2. severe motility disorders (e.g., achalasia, gastroparesis, pseudoobstruction) 3. pregnancy 4. cardiac pacemaker or implanted electro-medical devices

Keywords: capsule endoscopy gastrointestinal hemorrhage
does the incremental shuttle walk test predict the development of a hospital acquired pneumonia in patients undergoing elective oesophagectomy: a prospective cohort study

Conditions: Oesophageal Cancer

Summary: the purpose of this study was to assess the predictive value of the incremental shuttle walk test on rates of hospital acquired pneumonia for patients undergoing oesophagectomy.

field tests to objectively measure functional capacity are becoming of greater importance when looking to assess an individual's fitness for surgery. one such field test is the incremental shuttle walk test (iswt). an externally paced, maximal excursion test, the iswt is a simple and easily reproducible test that is widely used within cardiac and pulmonary populations and shown to correlate well with vo2 mas on a cardiopulmonary exercise test. previous studies looking at the benefit of the iswt in predicting post-operative outcomes within the oesophagastric population have demonstrated that walking less than 350 meters has been associated with significantly higher rates of mortality at 30 days and 3 years. no correlation between iswt and postoperative respiratory complications in this surgical population has been previously reported. this study aims to assess whether walking \<350 meters on an iswt predicts the development of hospital acquired pneumonias following an elective oesophagectomy

Eligibility criteria:
inclusion criteria: * consecutive patients with a diagnosis of oesophagogastric cancer listed for an elective oesophagectomy at a large uk tertiary hospital exclusion criteria: * patients who were unable to complete the walking test * patients deemed not fit for surgery * patients with a significant neurological event peri or post operatively

Keywords: physiotherapy shuttle walk test hospital acquired pneumonia outcomes oesophagectomy
evaluate the efficacy and safety of tqc2731 injection in patients with severe asthma.

Conditions: Severe Asthma

Summary: this is a phase ii, multicenter, double-blind, randomized, parallel group, placebo-controlled clinical study to evaluate the effect of three doses of tqc2731 on annualized asthma exacerbation rates(aaer) in adult subjects with poor control of severe asthma. it is estimated that 220 subjects will be included. the subjects will receive tqc2731 (70 mg q4w, 210 mg q4w, 420 mg q4w) or placebo (q4w) administered by subcutaneous (sc) in the ratio of 1:1:1:1. the study comprised a 5 to 6-week screening period, a 52-week treatment period and a 12-week follow-up period. during the treatment period, the study drug will be administered from day 0 until week 48. the study drug was not administered at the 52nd week.


Eligibility criteria:
inclusion criteria: * 1 age. 18-75 * 2 documented physician-diagnosed asthma for at least 12 months before visit 1. * 3 subjects who have received a physician-prescribed asthma controller medication with medium or high dose inhaled glucocorticosteroid (ics) for at least 12 months before visit 1. * 4 documented treatment with a total daily dose of either medium or high dose ics for at least 3 months before visit 1. * 5 at least one additional maintenance asthma controller medication such as long acting β2 receptor agonist (laba), leukotriene receptor antagonist (ltra), theophylline, long-acting muscarinic antagonists (lama), sodium cromoglycate, etc. is required according to standard practice of care and must be documented for at least 3 months. * 6 morning pre-bd fev1 \<80% predicted normal at visit 2 or visit 2a. * 7 evidence of asthma as documented by either: documented historical reversibility of fev1 ≥12% and ≥200 ml in the previous 12 months before visit 1 or post-bd (albuterol/salbutamol) reversibility of fev1 ≥12% and ≥200 ml during screening at visit 2 or visit 2a. * 8 documented history of at least 2 asthma exacerbation events within 12 months before visit 1. * 9 acq-6 score ≥1.5 at visit 1 * 10 body weight ≥ 40 kg at visit 1. exclusion criteria: * 1 pulmonary disease other than asthma. * 2 history of cancer. * 3 current smokers or subjects with smoking history ≥10 pack-years. * 4 hepatitis b, c, human immunodeficiency virus (hiv) or syphilis. * 5 history of anaphylaxis following any biologic therapy. * 6 history of chronic alcohol or drug abuse within 12 months. * 7 history of a clinically significant infection. * 8 pregnant or breastfeeding.
oral care of patients treated with anti-rank-ligand antibodies for a giant cell tumour

Conditions: Giant Cell Tumors

Summary: giant cell tumors are mostly benign tomoral processes, most often responsible for areas of osteolysis in the metaphysoepiphyseal area of long bones, representing 5-6% of primary bone tumors. the bone weakening induced by these beaches leads to pain and risk of fracture, and this is what leads the patient to consult. these tumors are found particularly in the young adult population between 20 and 40 years old, are locally aggressive, but malignant transformations and metastases (pulmonary) are quite rare. in this study, the investigators wish to retrospectively study the oral care of patients who presented with a giant cell tumor and were treated with denosumab at the university hospital of strasbourg and their associated oral follow-up


Eligibility criteria:
inclusion criteria: * adult subject, having presented a giant cell tumor treated with adjuvant or neoadjuvant denosumab at the hus from 01/01/2014 to 08/31/2022. * subjects who have not expressed their opposition to the reuse of their data for scientific research purposes. exclusion criteria: * subject having expressed their opposition to the retrospective reuse of their data for scientific research purposes * pathology finally labeled other than giant cell tumour. * treatment with denosumab was not initiated because of death, change in treatment protocol, etc. * absence of oral follow-up element.

Keywords: giant cell tumors anti-rank-ligand antibodies
effect of exendin-(9-39) on glycemic control in subjects with congenital hyperinsulinism

Conditions: Congenital Hyperinsulinism

Summary: the purpose of this study is to determine if exendin-(9-39), an antagonist of the glucagon-like peptide-1 (glp-1) receptor with effects on the pancreatic beta cell, increases fasting blood glucose levels in subjects with congenital hyperinsulinism.

this is an open-label, pilot study , to determine if exendin-(9-39), an antagonist of the glucagon-like peptide-1 (glp-1) receptor with effects on the pancreatic beta cells, increases fasting blood glucose levels in subjects with congenital hyperinsulinism. our overall hypothesis is that abnormal glp-1 secretion resulting from dysfunctional nutrient sensing in intestinal l-cells plays a role in the dysregulated insulin secretion characteristic of this disorder, and that antagonism of the glp-1 receptor will increase fasting blood glucose levels. aim 1. to evaluate the dose of exendin-(9-39) required to elevate fasting blood glucose levels in subjects with congenital hyperinsulinism due to katp channel mutations. aim 2. to determine therapeutic plasma levels, plasma half-life and pharmacokinetics of exendin-(9-39) during an intravenous short-term infusion in subjects with congenital hyperinsulinism due to adenosine triphosphate (atp)-sensitive potassium channel (katp) mutations.

Eligibility criteria:
inclusion criteria: * subjects with congenital hyperinsulinism exclusion criteria: * acute medical illness * history of other systemic chronic disease such as cardiac failure, renal insufficiency, hepatic insufficiency, chronic obstructive pulmonary disease, anemia, or uncontrolled hypertension * pregnancy * diabetes mellitus * use of medications that affect glucose metabolism, such as glucocorticoids, beta agonists, diazoxide and octreotide. * subjects will be eligible to participate 48 hrs after the last dose of octreotide and 72 hrs after last dose of diazoxide

Keywords: hyperinsulinism hypoglycemia katp channel kir6.2
study of niclosamide in moderate and severe hospitalized coronavirus-19 (covid-19) patients

Conditions: COVID-19

Summary: study of ana001 in moderate and severe covid-19 patients

this is a 2 part, phase 2/3 multi-center, double blinded, placebo-controlled study to assess the safety, tolerability, and efficacy of oral niclosamide (ana001) in moderate and severe hospitalized covid-19 patients compared to placebo.

Eligibility criteria:
key inclusion criteria: 1. provide written informed consent prior to performing study procedures 2. hospitalized. 3. male or female ≥18 years of age 4. positive for severe acute respiratory syndrome coronavirus 2 5. presence of symptoms of lower respiratory tract infection (lrti) including at least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, or more significant lower respiratory tract symptoms, including shortness of breath 6. at least 1 of the following: respiratory rate (rr) ≥20 breaths per minute, room air oxygen saturation (spo2) \ 38.3°c 7. women of childbearing potential must agree to abstinent or use at least 1 form of contraception not including hormonal contraception from the day of screening through day 30 key exclusion criteria: 1. hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours) 2. patient is not anticipated to survive \>48 hours or is under palliative care 3. evidence of critical illness, defined by at least 1 of the following: * respiratory failure requiring at least 1 of the following: 1. endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula 2. noninvasive positive pressure ventilation (nipvv), or 3. extracorporeal membrane oxygenation (ecmo) or clinical diagnosis of respiratory failure * shock (defined by systolic blood pressure (bp) \<90 mm hg, or diastolic blood pressure (bp) \<60 mm hg or requiring vasopressors), or * multi-organ dysfunction/failure 4. severe central nervous system (cns) conditions 5. chronic kidney disease requiring dialysis 6. known allergy to the study drug or salicylate containing medications. 7. suspected and/or confirmed pregnancy or breastfeeding 8. current or planned participation in any other clinical trial of a treatment being developed under a us investigational new drug (ind) or emergency use authorization (eua). 9. patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (mabs) or plasma transfusions) for chronic disease conditions.

Keywords: corona virus disease (covid-19) niclosamide antiviral immunomodulator oral niclosamide infection acute respiratory distress syndrome (ards) cytokine dysregulation virus viral anthelmintic anti-inflammatory bronchodilator antineoplastic ana001 moderate covid-19 ards acute respiratory distress syndrome hospitalized covid-19
an observational study for ambrisentan

Conditions: Hypertension, Pulmonary

Summary: the purpose of the programme is to collect safety data on ambrisentan when used in clinical practice

the purpose of the programme is to collect safety data on ambrisentan when used in clinical practice

Eligibility criteria:
subjects who have been prescribed ambrisentan for a medically appropriate use (see approved product label)

Keywords: pulmonary arterial hypertesion observational safety
frequency of surgical site infection in abdominal hernia with gentamycin spray on mesh versus no spray

Conditions: Wound With Foreign Body (With or Without Infection)

Summary: patient diagnosed with para umbilical hernia, umbilical hernia, epigastric will be selected for the study. sampling technique will be systematic with every 2nd patient being exposed to gentamycin spray during mesh repair. . each procedure took 90 to 120 minutes approximately. all patients underwent open abdominal hernioplasty operated on elective list. after placing onlay polypropylene mesh fixed with 2-0 prolene and gentamicin 160 mg injection will be sprayed over the secured mesh. close active suction drain will be placed in subcutaneous space. finally we will close the skin with prolene 2-0 with vertical mattress suture or stapler.

patients and methods: the study will be conducted at dow university hospital karachi, ojha campusa. the subjects included were elective patients operated for abdominal hernias. sample size calculated for a larger study with 50% frequency, and 99% confidence levels, using openepi was found to be 664. according to connelly\*, the sample size of pilot study should be 10% of the sample size of a larger pilot study. as it is a pilot study, the sample size for this study was found to be 66. we will take the informed consent before including the patient in the study. inclusion criteria following hernia operated on elective list * para umbilical hernia * umbilical hernia * epigastric hernia exclusion criteria * all above hernia operated in emergency * inguinal hernia sampling technique will be systematic with every 2nd patient being exposed to gentamycin spray during mesh repair. . each procedure took 90 to 120 minutes approximately. all patients underwent open abdominal hernioplasty operated on elective list. after placing onlay polypropylene mesh, fixed with 2-0 prolene and gentamicin 160 mg injection will be sprayed over the secured mesh. close active suction drain will be placed in subcutaneous space. finally skin will be close with prolene 2-0 with vertical mattress suture or stapler. all patients discharge on a day care basis with follow-ups in the opd out patient department for any post-operative ssi surgical site infection for a period of two weeks. drains will be remove once no or less than 20 ml serosanguinous/ serous discharge in 24 hours.

Eligibility criteria:
inclusion criteria: elective surgery; para umbilical hernia, umbilical and epigastric hernia, exclusion criteria: emergency admission incissional hernia inguinal hernia -

Keywords: ssi wound infection
ulnar nerve deep branch compression by a ganglion

Conditions: Guyon's Canal; Nerve Compression

Summary: ulnar nerve compression is common at the elbow, but less common at the wrist. the purposes of this study are to report a series of 9 patients with pure ulnar nerve deep branch compression by a ganglion and to evaluate the outcome following a surgical treatment. according modified bishop's scoring system, the investigators would evaluate postoperative results of this uncommon nerve lesion.

pre- and post-operative physical examination include assessment of tenderness and strength (grip and pinch). grip strength and tip pinch strength between the thumb and index finger are measured using the e-link system. according bishop's scoring system, the investigators redesign a questionnaire for comprehensive assessment of this uncommon nerve lesion.

Eligibility criteria:
inclusion criteria: ulnar nerve deep branch compression by a ganglion - exclusion criteria: ulnar nerve deep branch compression caused by other reasons -

Keywords: deep branch of the ulnar nerve distal ulnar nerve compression